Completed PHASE1 INTERVENTIONAL 2-arm NCT05469126

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants

Sponsor: Eli Lilly and Company

Conditions Healthy

Interventions Clarithromycin LY3502970

Updated 4 times since 2022 Last updated: Nov 23, 2022 Started: Aug 1, 2022 Primary completion: Nov 3, 2022 Completion: Nov 3, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Eli Lilly and Company leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2022 — Dec 2022 [monthly]

Active Not Recruiting PHASE1

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore